14 completed, 4 terminated, 2 unknown, 1 active not recruiting. 22 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 14, Terminated 4, Unknown 2, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Completed 2 |
Follow Growth Hormone Deficiency: new trials by email Literature Review of Growth Hormone Deficiency trials Research Report on Growth Hormone Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) LUM-201 - Growth Hormone Deficiency | Phase 2 | Enrolling by invitation | Lumos Pharma | 60 | 2023-08-01 | 2024-02-15 |
| Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) LUM-201 - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 15 | 2022-02-18 | 2026-05-15 |
| PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) LUM-201 - Growth Hormone Deficiency | Phase 2 | Active not recruiting | Lumos Pharma | 24 | 2021-07-14 | 2023-10-04 |
| Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) LUM-201, rhGH Norditropin® pen (34 µg/kg) - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 104 | 2020-12-31 | 2026-06-17 |
| Growth Hormone Replacement Therapy for Retried Professional Football Players Growth Hormone, Placebo - TBI (Traumatic Brain Injury), Concussion, Brain | Phase 2 | Unknown | Center for Neurological Studies | 42 | 2019-10-08 | 2023-02-08 |
| Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Y-shape pegylated somatropin, Norditropin®, Norditropin - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 434 | 2018-12-26 | 2024-01-24 |
| Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency GX-H9, Genotropin - Growth Hormone Deficiency | Phase 2 | Completed | Genexine, Inc. | 56 | 2016-01-18 | 2020-04-20 |
| Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency TV-1106, Recombinant human growth hormone - Growth Hormone Deficiency | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 52 | 2013-03-31 | 2021-12-10 |
| Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg - Obesity, Short Stature | Phase 1 / Phase 2 | Terminated | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 37 | 2011-07-01 | 2018-12-17 |
| Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I) Norditropin SimpleXx (growth hormone) - Growth Hormone Deficiency | Phase 2 | Completed | Aarhus University Hospital | 8 | 2010-10-01 | 2014-01-09 |
| Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency Somatropin - Growth Hormone Deficiency | Phase 2 | Unknown | Altus Pharmaceuticals | 36 | 2009-03-01 | 2009-05-07 |
| Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth hormone releasing hormone (GHRH) 1-44, Placebo - Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | Completed | Massachusetts General Hospital | 60 | 2008-07-01 | 2017-12-13 |
| Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD). ARX201 - Growth Hormone Deficiency | Phase 2 | Completed | Ambrx, Inc. | 36 | 2008-07-01 | 2009-10-12 |
| Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors Recombinant Human Growth Hormone, Recombinant Human IGF-1 - Growth Hormone Deficiency | Phase 1 / Phase 2 | Terminated | Columbia University | 5 | 2008-01-01 | 2024-07-17 |
| Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Somatotropin - Growth Hormone Deficiency, Chronic Heart Failure | Phase 2 | Completed | Federico II University | 28 | 2007-01-01 | 2012-10-18 |
| A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency PHA-794428 - Growth Hormone Deficiency | Phase 2 | Terminated | Pfizer | 136 | 2006-07-01 | 2011-05-18 |
| Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children pegylated Somatropin, Jintropin AQ - Growth Hormone Deficiency | Phase 2 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 101 | 2006-05-01 | 2017-07-31 |
| A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency PHA-794428 - Growth Hormone Deficiency | Phase 2 | Terminated | Pfizer | 32 | 2006-04-01 | 2011-05-16 |
| Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial Somatotropin - Heart Failure, Growth Hormone Deficiency | Phase 2 | Completed | Federico II University | 56 | 2004-12-01 | 2012-11-19 |
| Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group), amitriptyline, fluoxetine and tramadol alone (control group) - Fibromyalgia, Growth Hormone Deficiency | Phase 2 | Completed | Centro Medico Teknon | 2004-05-01 | 2007-07-06 |
Showing 20 of 22. Sign in to see all of them.
Dwarfism, Pituitary (22) · Hypopituitarism (2) · Brain Concussion (1) · Brain Injuries, Traumatic (1) · Cognition Disorders (1) · Dwarfism (1) · Fibromyalgia (1) · Heart Failure (1) · Hypogonadism (1) · Myocardial Ischemia (1) · Obesity (1) · Obesity, Abdominal (1) · Overweight (1)
Bone Diseases (22) · Bone Diseases, Developmental (22) · Bone Diseases, Endocrine (22) · Brain Diseases (22) · Central Nervous System Diseases (22) · Endocrine System Diseases (22) · Hypothalamic Diseases (22) · Musculoskeletal Diseases (22) · Nervous System Diseases (22) · Pituitary Diseases (22) · Dwarfism (21) · Hypopituitarism (20) · Body Weight (2) · Nutrition Disorders (2) · Nutritional and Metabolic Diseases (2)
Human Growth Hormone (7) · Growth Hormone (6) · Amitriptyline (1) · Control Groups (1) · Fluoxetine (1) · GX-H9 (1) · Growth Hormone-Releasing Hormone (1) · Injections (1) · Testosterone (1) · Tramadol (1) · albusomatropin (1) · tesamorelin (1)
Lumos Pharma (4) · Federico II University (2) · Pfizer (2) · Aarhus University Hospital (1) · Altus Pharmaceuticals (1) · Ambrx, Inc. (1) · BioPartners GmbH (1) · Center for Neurological Studies (1) · Centro Medico Teknon (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Columbia University (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Genexine, Inc. (1) · Massachusetts General Hospital (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
United States (10) · Germany (3) · Israel (3) · Poland (3) · Australia (2) · Belgium (2) · Czechia (2) · Denmark (2) · France (2) · Hungary (2) · Italy (2) · Slovakia (2) · Spain (2) · Ukraine (2) · United Kingdom (2)
Albert Nadal, MD (1) · Antonio Cittadini, MD (1) · Cecilia Lansang, MD (1) · Ference Peter, MD (1) · Guillem Cuatrecasas, MD (1) · Jack A Yanovski, M.D. (1) · Jungwon Woo (1) · Mihaly Juhasz, MD (1) · Pamela U. Freda, M.D. (1) · Peter J. Snyder, MD (1) · Randall R Benson, MD (1) · Steven K. Grinspoon, MD (1) · Torben Laursen, professor (1)
PMID 18053120, PMID 19654233, PMID 23015655, PMID 24178787, PMID 24291224, PMID 24423356, PMID 28566441, PMID 36034448
R01AR050618 (1), R01HL085268 (1)